158 related articles for article (PubMed ID: 35681425)
1. Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455.
Darwis NDM; Horigome E; Li S; Adachi A; Oike T; Shibata A; Hirota Y; Ohno T
Cells; 2022 May; 11(11):. PubMed ID: 35681425
[TBL] [Abstract][Full Text] [Related]
2. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
[TBL] [Abstract][Full Text] [Related]
3. FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy.
Darwis NDM; Nachankar A; Sasaki Y; Matsui T; Noda SE; Murata K; Tamaki T; Ando K; Okonogi N; Shiba S; Irie D; Kaminuma T; Kumazawa T; Anakura M; Yamashita S; Hirakawa T; Kakoti S; Hirota Y; Tokino T; Iwase A; Ohno T; Shibata A; Oike T; Nakano T
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540114
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
Hanes R; Munthe E; Grad I; Han J; Karlsen I; McCormack E; Meza-Zepeda LA; Stratford EW; Myklebost O
Cells; 2019 Feb; 8(2):. PubMed ID: 30795553
[No Abstract] [Full Text] [Related]
5. A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.
Michael M; Bang YJ; Park YS; Kang YK; Kim TM; Hamid O; Thornton D; Tate SC; Raddad E; Tie J
Target Oncol; 2017 Aug; 12(4):463-474. PubMed ID: 28589492
[TBL] [Abstract][Full Text] [Related]
6. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.
Kabashima A; Hirsova P; Bronk SF; Hernandez MC; Truty MJ; Ilyas SI; Kaufmann SH; Gores GJ
J Hepatol; 2018 Jun; 68(6):1228-1238. PubMed ID: 29408314
[TBL] [Abstract][Full Text] [Related]
8. LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance.
Wu D; Guo M; Min X; Dai S; Li M; Tan S; Li G; Chen X; Ma Y; Li J; Jiang L; Qu L; Zhou Z; Chen Z; Chen L; Xu G; Chen Y
Chem Commun (Camb); 2018 Oct; 54(85):12089-12092. PubMed ID: 30298149
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
[TBL] [Abstract][Full Text] [Related]
10. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance.
Dehghanian F; Alavi S
Sci Rep; 2021 Aug; 11(1):16593. PubMed ID: 34400727
[TBL] [Abstract][Full Text] [Related]
12. The combination of olaparib and camptothecin for effective radiosensitization.
Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
[TBL] [Abstract][Full Text] [Related]
13. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
[TBL] [Abstract][Full Text] [Related]
14. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.
Zhao G; Li WY; Chen D; Henry JR; Li HY; Chen Z; Zia-Ebrahimi M; Bloem L; Zhai Y; Huss K; Peng SB; McCann DJ
Mol Cancer Ther; 2011 Nov; 10(11):2200-10. PubMed ID: 21900693
[TBL] [Abstract][Full Text] [Related]
15. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
[TBL] [Abstract][Full Text] [Related]
17. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
Liu B; Chen W; Li H; Li F; Jin X; Li Q
Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
[TBL] [Abstract][Full Text] [Related]
19. Digoxin enhances radiation response in radioresistant A549 cells by reducing protein phosphatase 2A.
Lee JY; Kim MS; Lee MS; Ju JE; Chung N; Jeong YK
Biosci Rep; 2017 Nov; 37(6):. PubMed ID: 29070518
[TBL] [Abstract][Full Text] [Related]
20. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
